ACR 2022 Tweet by David Liew

Sjogren’s is tough to study, isn’t it?

LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with:
- ESSDAI (primary, obj dx activity) ✅
- auto-Ab ✅
- all patient outcomes ❎

Has already exceeded many attempts
Even then, still some limitations

ABST1113 #ACR22 @RheumNow